Last updated on November 2017

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor


Brief description of study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Study Medication in Subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least one TNF Inhibitor

Detailed Study Description

This is a 6 month study examining the safety and efficacy of an investigational medication in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.

Clinical Study Identifier: TX5279

Contact Investigators or Research Sites near you

Start Over

Jacob Aelion

West Tennessee Research Institute
Jackson, TN USA

Herbert Baraf

The Center For Rheumatology And Bone Research
Wheaton, MD USA

Charles Birbara

Clinical Pharmacology Study Group
Worcester, MA USA

Melvin Churchill

Physician Research Collaboration, LLC
Lincoln, NE USA

Asif Cochinwala

Pioneer Research Solutions, Inc.
Houston, TX USA

Pamela Freeman

Rheumatology Associates of Central Florida, PA
Orlando, FL USA

Geoffrey Gladstein

New England Research Associates, LLC
Trumbull, CT USA

Michael Kohen

Millennium Research
Ormond Beach, FL USA

Michael Luggen

Cincinnati Rheumatic Disease Study Group, Inc.
Cincinnati, OH USA

John Tesser

Arizona Arthritis & Rheumatology Research, PLLC
Glendale, AZ USA